Myeloma Disproportionately Impacts Black Patients
How Biomarker Testing May Help Inform Your Advanced Ovarian Cancer Treatment
This article is sponsored by AstraZeneca and Merck.
The power of a strong doctor-patient partnership and positivity when fighting lymphoma
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) cancer survivor Louise (left) and her oncologist, Dr. Ruemu Birhiray (right), built a lasting relationship as they navigated Louise’s diagnosis and relapse. This article is sponsored by MorphoSys and Incyte.
GVHD Care Starts at Home: How a Couple Learned to Lean on Each Other to Battle this Rare Disease
Sponsored by Incyte
Exploring A Patient’s Journey with Malignant PEComa
This article is sponsored by Aadi Bioscience, Inc.
Supportive care medicine is key to truly comprehensive cancer care
City of Hope sets the bar for treating people, not just diseases.
A HELPING HAND: Advice on Caring for Someone With Non-Small Cell Lung Cancer From Those Who Do It
Care partners need help, too! That’s why this informational booklet was created. It’s full of practical advice from people who have been in your shoes, caring for someone with non-small cell lung cancer.
Immunocompromised: Navigating the COVID-19 Pandemic while Living with CLL
Learn about the disproportionate impact that the COVID-19 pandemic has on immunocompromised patients with chronic lymphocytic leukemia (CLL), and hear potential solutions from leading CLL experts.
Starting Treatment for Small Cell Lung Cancer? Hear From an Oncology Nurse and a Cancer Patient.
Cindy Cherry, MSN, AGNP-C, and cancer patient Dorothy T. share their experiences with cancer and how they approach chemotherapy treatment.
HEAR MY VOICE: What People With Non-Small Cell Lung Cancer Want You to Know
Learn from survivors! Find out more about care communities, biomarker testing, and how to make the most of every appointment.
Understanding the Treatment Journey in Stage 3 Non-Small Cell Lung Cancer
Tips From an Oncology Nurse Practitioner That May Help With Treatment
Cindy Cherry, MSN, AGNP-C, is an oncology nurse practitioner in Greenville, North Carolina. She treats patients with all types of cancers, including extensive-stage small cell lung cancer (ES-SCLC).
How much do you know about certain chemotherapy side effects?
Learn more about the protection of bone marrow and how it may help lower the risk of bone marrow suppression for certain people with small cell lung cancer.
What you need to know about KRASG12C
In this episode of the “Cure Talks Cancer” Podcast, Dr. Spira a medical oncologist of the Virginia Cancer Specialists’ (VCS) discusses why KRASG12C is a prolific problem.
Sponsored Content: Managing Mantle Cell Lymphoma (MCL) after Relapsed on First Treatment
An interview with Dr. Luhua (Michael) Wang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center
Marialice’s Story with Chronic Lymphocytic Leukemia (CLL)
Treating CLL with CALQUENCE® (acalabrutinib)
Cholangiocarcinoma: Understanding Potential Paths For Treatment
There are multiple treatment patients for patients with cholangiocarcinoma, here's what you need to know about them.
What Patients with Cholangiocarcinoma Should Be Prepared for When Joining a Trial
A clinical research coordinator discusses how patients with cholangiocarcinoma can get involved in clinical trials, such as the phase 3 PROOF trial, as well as what they should know once they are enrolled.
Keeping Calm and Carrying on With CLL
CLL patient shares his experience with the disease and the importance of aiming to live his life to the fullest despite his diagnosis.
Building PROOF In Advanced Cholangiocarcinoma
Researchers hope the new PROOF trial will show that infigratinib, a targeted drug, will expand options in treating advanced cholangiocarcinoma. Patients are enrolling now.
Creating a Game Plan to Manage Multiple Myeloma
Patient Rod Gilmore shares his experience with multiple myeloma and the importance of creating a strategy to manage the disease.
HER2+ mBC: DESTINY-Breast04 Trial
The comparison of trastuzumab deruxtecan (DS-8201a) with standard chemotherapy is examined for patients with low levels of HER2 metastatic breast cancer and final thoughts on the future treatment landscape of HER2+ breast cancer.
Treating HER2-Positive Metastatic Breast Cancer: DESTINY-Breast02 and DESTINY-Breast03
The role of antibody drug conjugate DS-8201a (trastuzumab deruxtecan) in the treatment of HER2-positive metastatic breast cancer and an overview of the DESTINY-Breast02 and DESTINY-Breast03 trials.
Management of HER2 Expression in Breast Cancer
Ian E. Krop, MD, PhD, provides insight on HER2 expression in breast cancer, treatment for blocking HER2, and the management of newly diagnosed HER2+ metastatic breast cancer with T-DM1.
Cholangiocarcinoma: Targeting the Future
An expert on clinical and translational research in gastrointestinal malignancies discusses the promising future of targeted therapy in cholangiocarcinoma treatment.
Choosing Sides: Treatment Decisions for Recurrent Ovarian Cancer Must Consider Side Effects
Patients with ovarian cancer who experience disease recurrences can have potentially helpful options from a large array of drugs, each of which can bring on side effects. Luckily, doctors have a variety of ways to relieve or prevent these discomforts. At the same time, scientists are working to develop new treatments that may be both efficacious and easier for patients to tolerate.
Optune User Journey: Meet Steve
Watch a video about Steve, an Optune user. Learn how Steve manages his treatment while enjoying his favorite activities.
Understanding Metastatic Breast Cancer (MBC)
AstraZeneca highlights important facts about metastatic breast cancer.
2 Clarke Drive Cranbury, NJ 08512